Clinical Trials · NCT03013387

Dosimetry Guided PRRT With 90Y-DOTATOC

WithdrawnPhase 2Octreotide (Prohibited)
Phase
Phase 2
Recruitment status
Withdrawn
Sponsor
Sue O'Dorisio
Enrollment
0
Start date
Jan 2017
Locations
See registry
Primary endpoint
Treatment efficacy as assessed by change and defined as complete response, partial response or stable disease (CR+PR+SD)
View Octreotide compound reference